japan-header

JAPAN

Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.

Contribution to Group revenue

japan-contrib-1

Revenue contribution - by therapeutic category

japan-1
  • The Japanese pharmaceutical sector continues to be negatively impacted by regulated price revisions and was valued at USD80 billion as at 31 December 2017.

Source: December 2017 IMS

STATISTICS

Number of products launched:

9

(2017: 9)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:

0 – 2 years

USDnil

3 – 5 years

USDnil

Number of product recalls:

Nil

(2017: nil)

Average staff turnover:

20,0%

(2017: 20,7%)

Number of work-related fatalities:

Nil

(2017: nil)

Number of permanent employees:

japan-employees

Revenue – R’billion20182017 (CER)% change
Total1 9301 8127
Regional Brands29717273
Anaesthetics1 2131 2041
Thrombosis4857(16)
High Potency & Cytotoxics372379(2)